170 related articles for article (PubMed ID: 11849199)
1. Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide.
Thomas HD; Porter DJ; Bartelink I; Nobbs JR; Cole M; Elliott S; Newell DR; Calvert AH; Highley M; Boddy AV
Br J Clin Pharmacol; 2002 Jan; 53(1):83-91. PubMed ID: 11849199
[TBL] [Abstract][Full Text] [Related]
2. Influence of mesna on the pharmacokinetics of cisplatin and carboplatin in pediatric cancer patients.
Kangarloo SB; Gangopadhyay SB; Syme RM; Wolff JE; Glück S
Med Oncol; 2004; 21(1):9-20. PubMed ID: 15034209
[TBL] [Abstract][Full Text] [Related]
3. Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma.
Newell DR; Eeles RA; Gumbrell LA; Boxall FE; Horwich A; Calvert AH
Cancer Chemother Pharmacol; 1989; 23(6):367-72. PubMed ID: 2469544
[TBL] [Abstract][Full Text] [Related]
4. Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
Peng B; Tilby MJ; English MW; Price L; Pearson AD; Boddy AV; Newell DR
Br J Cancer; 1997; 76(11):1466-73. PubMed ID: 9400943
[TBL] [Abstract][Full Text] [Related]
5. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
[TBL] [Abstract][Full Text] [Related]
6. Dosage individualization of carboplatin and etoposide based on pharmacokinetic investigations.
Jaehde U
Int J Clin Pharmacol Ther; 1997 Feb; 35(2):76-8. PubMed ID: 9147713
[No Abstract] [Full Text] [Related]
7. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors.
Motzer RJ; Gulati SC; Tong WP; Menendez-Botet C; Lyn P; Mazumdar M; Vlamis V; Lin S; Bosl GJ
Cancer Res; 1993 Aug; 53(16):3730-5. PubMed ID: 8393380
[TBL] [Abstract][Full Text] [Related]
8. Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates.
Jacobs SS; Fox E; Dennie C; Morgan LB; McCully CL; Balis FM
Clin Cancer Res; 2005 Feb; 11(4):1669-74. PubMed ID: 15746072
[TBL] [Abstract][Full Text] [Related]
9. Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study.
You B; Tranchand B; Girard P; Falandry C; Ribba B; Chabaud S; Souquet PJ; Court-Fortune I; Trillet-Lenoir V; Fournel C; Tod M; Freyer G
Lung Cancer; 2008 Nov; 62(2):261-72. PubMed ID: 18442869
[TBL] [Abstract][Full Text] [Related]
10. Bioequivalence investigation of high-dose etoposide and etoposide phosphate in lymphoma patients.
Reif S; Kingreen D; Kloft C; Grimm J; Siegert W; Schunack W; Jaehde U
Cancer Chemother Pharmacol; 2001 Aug; 48(2):134-40. PubMed ID: 11561779
[TBL] [Abstract][Full Text] [Related]
11. Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee study.
Porter D; Boddy A; Thomas H; Lind M; Newell D; Calvert AH; Robson L; Brampton M; Abrahamsen D; Winograd B
Semin Oncol; 1996 Dec; 23(6 Suppl 13):34-44. PubMed ID: 8996574
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function.
Duong JK; Veal GJ; Nath CE; Shaw PJ; Errington J; Ladenstein R; Boddy AV
Br J Clin Pharmacol; 2019 Jan; 85(1):136-146. PubMed ID: 30261554
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of etoposide in rats with uranyl nitrate (UN)-induced acute renal failure (ARF): optimization of the duration of UN dosing.
Venkatesh P; Harisudhan T; Choudhury H; Mullangi R; Srinivas NR
Eur J Drug Metab Pharmacokinet; 2007; 32(4):189-96. PubMed ID: 18348467
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel.
Obasaju CK; Johnson SW; Rogatko A; Kilpatrick D; Brennan JM; Hamilton TC; Ozols RF; O'Dwyer PJ; Gallo JM
Clin Cancer Res; 1996 Mar; 2(3):549-52. PubMed ID: 9816202
[TBL] [Abstract][Full Text] [Related]
15. Use of microdialysis to study platinum anticancer agent pharmacokinetics in preclinical models.
Johansen MJ; Thapar N; Newman RA; Madden T
J Exp Ther Oncol; 2002; 2(3):163-73. PubMed ID: 12415633
[TBL] [Abstract][Full Text] [Related]
16. Amifostine (Ethyol): pharmacokinetic and pharmacodynamic effects in vivo.
van der Vijgh WJ; Korst AE
Eur J Cancer; 1996; 32A Suppl 4():S26-30. PubMed ID: 8976819
[TBL] [Abstract][Full Text] [Related]
17. A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. MRC Testicular Tumour Working Party.
Horwich A; Oliver RT; Wilkinson PM; Mead GM; Harland SJ; Cullen MH; Roberts JT; Fossa SD; Dearnaley DP; Lallemand E; Stenning SP;
Br J Cancer; 2000 Dec; 83(12):1623-9. PubMed ID: 11104556
[TBL] [Abstract][Full Text] [Related]
18. Phase I study and clinical pharmacological evaluation of daily oral etoposide combined with carboplatin in patients with lung cancer.
Ohune T; Fujiwara Y; Sumiyoshi H; Yamaoka N; Yamakido M
Jpn J Cancer Res; 1995 May; 86(5):490-500. PubMed ID: 7790322
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacokinetics and dose optimisation of carboplatin.
Duffull SB; Robinson BA
Clin Pharmacokinet; 1997 Sep; 33(3):161-83. PubMed ID: 9314610
[TBL] [Abstract][Full Text] [Related]
20. Use of a toxicity factor to explain differences in nephrotoxicity and myelosuppression among the platinum antitumour derivatives cisplatin, carboplatin and nedaplatin in rats.
Hanada K; Asano K; Nishimura T; Chimata T; Matsuo Y; Tsuchiya M; Ogata H
J Pharm Pharmacol; 2008 Mar; 60(3):317-22. PubMed ID: 18284811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]